Is IMMUNIC, INC. (IMUX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 22.2% / 30% | 0.4% / 30% | N/A | ✓ HALAL |
| DJIM | 0.6% / 33% | 22.2% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| MSCI | 2.5% / 33% | 87.3% / 33% | 1.7% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 22.2% / 33% | 0.4% / 33% | N/A | ✓ HALAL |
| FTSE | 2.5% / 33% | 87.3% / 33% | 1.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1653.1% | |
| Return on Assets (ROA) | -198.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$86M |
| Free Cash Flow | -$86M |
| Total Debt | $577,000 |
| Current Ratio | 0.7 |
| Total Assets | $24M |
Price & Trading
| Last Close | $1.26 |
| 50-Day MA | $0.93 |
| 200-Day MA | $0.83 |
| Avg Volume | 3.5M |
| Beta | 1.5 |
|
52-Week Range
$0.51
| |
About IMMUNIC, INC. (IMUX)
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IMMUNIC, INC. (IMUX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IMMUNIC, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IMMUNIC, INC.'s debt ratio?
IMMUNIC, INC.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are IMMUNIC, INC.'s key financial metrics?
IMMUNIC, INC. has a market capitalization of $142M. Return on equity stands at -1653.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.